<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>PlatCOVID</title>
    <link>/drugpanel/chlorpromazine/</link>
      <atom:link href="/drugpanel/chlorpromazine/index.xml" rel="self" type="application/rss+xml" />
    <description>PlatCOVID</description>
    <generator>Source Themes Academic (https://sourcethemes.com/academic/)</generator><language>en-us</language><copyright>BioHub - UFPE</copyright><lastBuildDate>Sun, 09 Sep 2018 00:00:00 +0000</lastBuildDate>
    <image>
      <url>/images/icon_hu7e12209333f22d741aca7d462871821f_9877_512x512_fill_lanczos_center_2.png</url>
      <title>PlatCOVID</title>
      <link>/drugpanel/chlorpromazine/</link>
    </image>
    
    <item>
      <title>CHLORPROMAZINE</title>
      <link>/drugpanel/chlorpromazine/info/</link>
      <pubDate>Sun, 05 May 2019 00:00:00 +0100</pubDate>
      <guid>/drugpanel/chlorpromazine/info/</guid>
      <description>
&lt;script src=&#34;/rmarkdown-libs/kePrint/kePrint.js&#34;&gt;&lt;/script&gt;


&lt;hr /&gt;
&lt;p align=&#34;left&#34; style=&#34;font-size:16px&#34;&gt;
DrugBank ID: &lt;a href=&#39;https://www.drugbank.ca/drugs/db00477&#39; target=&#39;_blank&#39;&gt;db00477&lt;/a&gt; &lt;br&gt;
DrugCentral: &lt;a href=&#34;http://drugcentral.org/?q=chlorpromazine&#34; target=&#34;_blank&#34;&gt;chlorpromazine&lt;/a&gt; &lt;br&gt;
Synonymous :3-(2-chloro-10h-phenothiazin-10-yl)-n,n-dimethyl-1-propanamine | 3-(2-chlorophenothiazin-10-yl)-n,n-dimethyl-propan-1-amine | chlorpromazine | chlorpromazinum | clorpromazina | cpz | n-(3-dimethylaminopropyl)-3-chlorophenothiazine
&lt;/p&gt;
&lt;p&gt;&lt;br&gt;&lt;/p&gt;
&lt;hr /&gt;
&lt;div id=&#34;drug-sentece-context&#34; class=&#34;section level2&#34;&gt;
&lt;h2&gt;Drug Sentece Context&lt;/h2&gt;
&lt;br&gt;
&lt;p style=&#34;font-size:12px&#34; align=&#34;center&#34;&gt;
&lt;strong&gt;Table 1.&lt;/strong&gt; Analysis of context sentence of &lt;em&gt;chlorpromazine&lt;/em&gt; gene in 3 abstracts.
&lt;/p&gt;
&lt;table class=&#34;table table-striped&#34; style=&#34;width: auto !important; margin-left: auto; margin-right: auto;&#34;&gt;
&lt;thead&gt;
&lt;tr&gt;
&lt;th style=&#34;text-align:center;position: sticky; top:0; background-color: #FFFFFF;&#34;&gt;
pmid
&lt;/th&gt;
&lt;th style=&#34;text-align:center;position: sticky; top:0; background-color: #FFFFFF;&#34;&gt;
sentence
&lt;/th&gt;
&lt;/tr&gt;
&lt;/thead&gt;
&lt;tbody&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;/publication/32387014&#34; target=&#34;_blank&#34;&gt;32387014&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Chlorpromazine (CPZ) is a phenothiazine derivative widely used in clinical routine in the treatment of acute and chronic psychoses.
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;/publication/32425222&#34; target=&#34;_blank&#34;&gt;32425222&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Chlorpromazine (CPZ), a phenothiazine derivative, is also known for its antiviral activity via the inhibition of clathrin-mediated endocytosis.
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;/publication/32493475&#34; target=&#34;_blank&#34;&gt;32493475&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Weight less than 40 Kg.Participant with any immunosuppressive condition or hematological disease.Treatment with drugs that may prolong QT in the last month before randomization for more than 7 days including: azithromycin, chlorpromazine, cisapride, clarithromycin, domperidone, droperidol, erythromycin, halofantrine, haloperidol, lumefantrine, mefloquine, methadone, pentamidine, procainamide, quinidine, quinine, sotalol, sparfloxacin, thioridazine, amiodarone.Hereditary intolerance to galactose, Lapp lactase deficiency or glucose or galactose malabsorption.Treatment with fluvoxamine.Treatment with benzodiazepines or benzodiazepine analogues such as zolpidem, zopiclone or zaleplon.Pregnancy.Breastfeeding.History of potentially immune derived diseases such as: lupus, Crohnâ€™s disease, ulcerative colitis, vasculitis or rheumatoid arthritis.Insulin-dependent diabetes mellitus.Known history of hypersensitivity to the study drug or any of its components.Patients that should not be included in the study at the judgment of the research team.
&lt;/td&gt;
&lt;/tr&gt;
&lt;/tbody&gt;
&lt;/table&gt;
&lt;/div&gt;
</description>
    </item>
    
  </channel>
</rss>
